Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A substantial number of patients with mania have significant concomitant depressive features, and they may respond differently to mood stabilizers than patients with pure mania. This post-hoc analysis explored the response characteristics of olanzapine versus placebo in bipolar I manic patients with dysphoric and nondysphoric mania (differentiated by baseline Hamilton Depression Rating Scale [HAM-D] score of >20). Two similar, double-blind, randomized trials comparing olanzapine, 5-20 mg, to placebo were pooled for these analyses (N = 246). Mean changes in Young-Mania Rating Scale (Y-MRS) and HAM-D scores during 3 weeks of treatment were examined. Twenty-eight percent of patients had dysphoric mania (olanzapine, n = 33; placebo, n = 35). Among these patients, olanzapine-treated patients had greater improvement within 1 week than did placebo-treated patients on both mania ratings (Y-MRS: -9.7 vs. -3.0 points; = 0.011) and depressive symptom ratings (HAM-D: -9.9 vs. -5.4 points; = 0.025). Among those manic subjects without prominent depressive symptoms (olanzapine, n = 91; placebo, n = 87), mean Y-MRS improvement from baseline to endpoint with olanzapine (-11.5 points) versus placebo (-6.13 points) was comparable to the improvement seen with olanzapine versus placebo in the dysphoric mania subgroup ( = 0.476, test of interaction). In acutely ill manic patients with significant depressive symptoms, olanzapine demonstrated a broad spectrum of efficacy, effectively treating both manic and depressive symptoms. The magnitude of the antimanic response appears similar, regardless of baseline depressive features. Additional experience with putative mood stabilizers and atypical agents in mixed mania should include an exploration of their efficacy in treating both manic and depressive mood symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Self-citationTreatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations
Thase, M. E. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230043006 · Cited by 515
Course of the Manic-Depressive Cycle and Changes Caused by Treatments
Kukopulos, A., Reginaldi, D., Laddomada, P., Floris, G., Serra, G., & Tondo, L. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-1019628 · Cited by 436
Flupenthixol decanoate in recurrent manic‐depressive illness: A COMPARISON WITH LITHIUM
Ahlfors, U. G., Baastrup, P. C., Dencker, S. J., Elgen, K., Lingjærde, O., Pedersen, V., Schou, M., & Aaskoven, O. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00778.x · Cited by 155
WEHR, T. A., & GOODWIN, F. K. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.7.906-a · Cited by 60
Cited by
Yatham, L. N., Kennedy, S. H., O'Donovan, C., Parikh, S., MacQueen, G., McIntyre, R., Sharma, V., Silverstone, P., Alda, M., Baruch, P., et al. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00219.x · Cited by 388
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Azorin, J.-M., Yatham, L., Mosolov, S., Möller, H.-J., Kasper, S., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1384850 · Cited by 187
“The other study (Baker et al. 2003) focussed on those patients with moderate-to-severe depressive symptoms (or dysphoric, defined by a HAM-D score 20 at baseline; n¼ 68), and compared them against the nondysphoric patients (n¼ 178).”
ResultBipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89
Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder
Fountoulakis, K. N., Vieta, E., Siamouli, M., Valenti, M., Magiria, S., Oral, T., Fresno, D., Giannakopoulos, P., & Kaprinis, G. S. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-27 · Cited by 76
“Olanzapine has the highest number of published randomized control trials (RCTs) [1,60,85,87,108-128] and a solid basis supporting its use in bipolar disorder [129],”
Metadata
- Authors
- Baker, R. W., Tohen, M., Fawcett, J., Risser, R. C., Schuh, L. M., Brown, E., Stauffer, V. L., Shao, L., & Tollefson, G. D.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2003-04
- Volume
- 23
- Issue
- 2
- Pages
- 132-137
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1964134854
- Cited by
- 62
- References
- 5
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo. https://app.cochat.ai/papers/10.1097/00004714-200304000-00005
- The paper
- Baker, R. W., Tohen, M., Fawcett, J., Risser, R. C., Schuh, L. M., Brown, E., Stauffer, V. L., Shao, L., & Tollefson, G. D. (2003). Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-200304000-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.